Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.65 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | ATR | Q13535 | 1/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.54 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.54 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 4/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369788 | 1.00 | PIK3CA (0.65) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL2369126 | 0.91 | PIK3CA (0.65) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL2369116 | 0.91 | PIK3CA (0.65) | PIK3CAPIK3CDCHEK1ATRPDCD1 | |
| SCHEMBL2369975 | 0.90 | PIK3CA (0.64) | PIK3CAPIK3CDMTORPIK3R1 | |
| SCHEMBL2369984 | 0.90 | PIK3CA (0.64) | PIK3CAPIK3CDMTORPIK3R1 | |
| SCHEMBL2369991 | 0.89 | PIK3CA (0.54) | PIK3CAPIK3CDMTOR | |
| SCHEMBL2369980 | 0.89 | PIK3CA (0.54) | PIK3CAPIK3CDMTOR | |
| SCHEMBL2369962 | 0.87 | PIK3CA (0.56) | PIK3CAPIK3CDMTORPIK3R1 | |
| SCHEMBL2369953 | 0.87 | PIK3CA (0.56) | PIK3CAPIK3CDMTORPIK3R1 | |
| SCHEMBL2370093 | 0.87 | PIK3CA (0.51) | PIK3CAPIK3CDMTORPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | claimed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | claimed |
| EP-2542536-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2013-01-09 | — | — | EP | claimed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | claimed |
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249129-B2 | Morpholino substituted urea derivatives as mTOR inhibitors | CELLZOME LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2542536-B1 | Morpholino substituted urea derivatives as mtor inhibitors | CELLZOME LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2542536-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2013-01-09 | — | — | EP | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107585-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196982-A1 | MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS | MTOR, EIF4E, EIF4A1 | PIK3CA 347/4885PIK3CD 562/4885CHEK1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.